Patents by Inventor Paul R. Hinton

Paul R. Hinton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8604177
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: December 10, 2013
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
  • Publication number: 20110183412
    Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 28, 2011
    Applicant: Facet Biotech Corpration
    Inventors: Paul R. Hinton, Naoya Tsurushita
  • Publication number: 20110165066
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Application
    Filed: March 8, 2011
    Publication date: July 7, 2011
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
  • Patent number: 7915388
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: March 29, 2011
    Assignee: Abbott Laboratories
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
  • Patent number: 7851600
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: December 14, 2010
    Assignees: Progenics Pharmaceuticals Inc., Facet Biotech Corporation
    Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximiliano Vasquez
  • Publication number: 20100196315
    Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
    Type: Application
    Filed: April 19, 2010
    Publication date: August 5, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Susan E. LACY, Emma FUNG, Jonathan P. BELK, Richard W. DIXON, Michael ROGUSKA, Paul R. HINTON, Shankar KUMAR
  • Patent number: 7732570
    Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: June 8, 2010
    Assignee: Facet Biotech Corporation
    Inventors: Paul R. Hinton, Naoya Tsurushita
  • Patent number: 7700739
    Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: April 20, 2010
    Assignee: Abbott Laboratories
    Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
  • Publication number: 20100047245
    Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
    Type: Application
    Filed: June 29, 2006
    Publication date: February 25, 2010
    Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
  • Patent number: 7666419
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: February 23, 2010
    Assignees: Progenics Pharmaceuticals Inc., Facet Biotech Corporation
    Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximillano Vasquez
  • Publication number: 20090232801
    Abstract: The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.
    Type: Application
    Filed: May 29, 2008
    Publication date: September 17, 2009
    Applicant: ABBOT LABORATORIES
    Inventors: Heinz Hillen, Stefan Barghorn, Ulrich Ebert, Andreas R. Striebinger, Patrick Keller, Boris Labkovsky, Paul R. Hinton, Veronica M. Juan
  • Publication number: 20090175847
    Abstract: The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.
    Type: Application
    Filed: May 29, 2008
    Publication date: July 9, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Stefan Barghorn, Ulrich Ebert, Heinz Hillen, Patrick Keller, Andreas R. Striebinger, Boris Labkovsky, Paul R. Hinton, Veronica M. Juan
  • Publication number: 20080287657
    Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
    Type: Application
    Filed: May 14, 2007
    Publication date: November 20, 2008
    Applicant: PDL BioPharma, Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita
  • Publication number: 20080226632
    Abstract: The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.
    Type: Application
    Filed: May 23, 2007
    Publication date: September 18, 2008
    Applicant: PDL BIOPHARMA, INC.
    Inventors: Nicholas F. Landolfi, Naoya Tsurshita, Paul R. Hinton, Shankar Kumar
  • Publication number: 20080171014
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Application
    Filed: September 7, 2007
    Publication date: July 17, 2008
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
  • Publication number: 20080107595
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii), two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Application
    Filed: October 16, 2006
    Publication date: May 8, 2008
    Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximiliano Vasquez
  • Patent number: 7361740
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: April 22, 2008
    Assignee: PDL BioPharma, Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez
  • Patent number: 7223393
    Abstract: The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: May 29, 2007
    Assignee: PDL Biopharma, Inc
    Inventors: Nicholas F. Landolfi, Naoya Tsurushita, Paul R. Hinton, Shankar Kumar
  • Patent number: 7217797
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: May 15, 2007
    Assignee: PDL Biopharma, Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez
  • Patent number: 7217798
    Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: May 15, 2007
    Assignee: PDL BioPharma, Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita